A prospective, interventional, randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of Bacillus coagulans LBSC in the treatment of acute diarrhea with abdominal discomfort

Maity, Chiranjit; Gupta, Anil Kumar

doi:10.1007/s00228-018-2562-x

Cited by 29 publications

(19 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The study showed that a 4 billion CFU/day of B. clausii along with ORS + Zinc supplement showed better efficacy than LAB in terms of faster recovery and achieving normal stool frequency. In fact, other spore-forming Bacillus like B. subtilis , B. coagulans , B. licheniformis , Clostridium butyricum and Lactobacillus spp., Pediococcus spp., Saccharomyces boulardii have clinically evaluated to exert therapeutic efficacies against various pediatric diarrhea including antibiotic-associated diarrhea [ 2 , 13 , 42 ].…”

Section: Discussionmentioning

confidence: 99%

“…Probiotics are potential live bio-therapeutics, which maintain intestinal microecology during or after antibiotic treatment through competition for epithelial receptors and nutrients, inhibition of epithelial and mucosal adhesion of pathogens, producing short chain fatty acids (SCFAs), balancing non-favorable intestinal pH (low), regulating immunity and synthesizing antimicrobial peptides and metabolites. With these mechanisms, probiotics provide a promising route to treat many gastrointestinal ailments including antibiotic-associated diarrhea without a risk of spreading antibiotic resistance among other microorganisms [ 12 , 13 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Therapeutic efficacy of probiotic Alkalihalobacillus clausii 088AE in antibiotic-associated diarrhea: A randomized controlled trial

Maity¹,

Gupta²

2021

Heliyon

Self Cite

View full text Add to dashboard Cite

The use of probiotics in gastrointestinal ailments has shown therapeutic effects. The imbalance of the microbiota caused by antibiotic treatment or others has been shown to be restored to normal with probiotic treatment. In this study, a genomically and phenotypically safe probiotic Alkalihalobacillus clausii 088AE has been evaluated for ameliorating antibiotic-associated diarrhea (AAD) in pediatrics (PE, n = 60, 2–10 years), adolescent and adults (AA, n = 60, 11–65 years) through a randomized controlled clinical trial. A. clausii 088AE was administered for seven days (PE, 4 and AA, 6 billion/day) and primary and secondary endpoints were evaluated on different visits. Compared to the respective placebo arms, A. clausii 088AE improved the diarrheal ( t ime t o l ast u nformed s tool and diarrheal frequency) conditions in children, adolescents and adults. A. clausii 088AE treatment decreased AAD-severity score on visit 5 in both pediatric (0.12 ± 0.33, 12.39 folds), adult and adolescent (0.54 ± 0.36, 2.34 folds) groups compared to those respective placebo arm (p < 0.05). A. clausii 088AE was well tolerated, did not cause significant changes in vital and clinical safety parameters and subjects reported no adverse effects or serious adverse reactions. A. clausii 088AE is safe and therapeutically effective against AAD, reducing onset of diarrhea and related severity symptoms including abdominal discomfort and pain, bloating and flatulence. A. clausii 088AE may be recommended as a live bio-therapeutic agent for improving clinical pathophysiology of gastrointestinal ailments, in particular antibiotic-associated diarrhea and related symptoms.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Therapeutic efficacy of probiotic Alkalihalobacillus clausii 088AE in antibiotic-associated diarrhea: A randomized controlled trial

Maity¹,

Gupta²

2021

Heliyon

Self Cite

View full text Add to dashboard Cite

show abstract

“…B. coagulans is a sporeforming bacterium that produces lactic acid. B. coagulans spores are probiotics and have beneficial effects in humans, such as amelioration of irritable bowel syndrome [12,13], bacterial vaginosis [14], and intestinal disorders [15][16][17], and absorption of amino acids from proteins [18,19]. In addition, their use in broilers and fish yields growth-promoting and disease-preventing effects [20,21].…”

Section: Discussionmentioning

confidence: 99%

Isolation of food-derived bacteria inducing interleukin-22 in B cells

Kumazawa

Kotake

Nishimura³

et al. 2020

Bioscience of Microbiota, Food and Health

View full text Add to dashboard Cite

Recently, we found a novel function of the lactic acid bacterium Tetragenococcus halophilus derived from miso, a fermented soy paste, that induces interleukin (IL)-22 production in B cells preferentially. IL-22 plays a critical role in barrier functions in the gut and skin. We further screened other bacteria species, namely, Enterococcus, Lactobacillus, Lactococcus, Leuconostoc, Weissella, Pediococcus, and Bacillus, in addition to Tetragenococcus and found that some of them possessed robust IL-22-inducible function in B cells in vitro. This process resulted in the augmented expression of activation markers CD86 and CD69 on B and T cells, respectively. However, these observations were not correlated with IL-22 production. We isolated Bacillus coagulans sc-09 from miso and determined it to be the best strain to induce robust IL-22 production in B cells. Furthermore, feeding B. coagulans sc-09 to mice augmented the barrier function of the skin regardless of gut microbiota.

show abstract

“…Among all probiotics, the bacterial species belonging to the genus Bacillus are indeed remarkable for their high tolerance to gastric acids and bile salts ( 1 ). They have been reported to play a significant role in preventing irritable bowel syndrome infection ( 2 ), enhancing immunity ( 3 ), inhibiting the growth of pathogenic bacteria ( 4 ), and treating diarrheal diseases in the human body ( 5 ). Bacillus coagulans was described at the Iowa Agricultural Experiment Station in 1915 by Sarles and Hammer ( 6 ).…”

Section: Announcementmentioning

confidence: 99%

Complete Genome Sequence of Bacillus coagulans BC01, a Promising Human Probiotic Strain Isolated from Thick Broad Bean Sauce

Yang¹,

Yu²,

Ouyang³

et al. 2021

Microbiol Resour Announc

View full text Add to dashboard Cite

We report the whole-genome sequence of a promising human probiotic, Bacillus coagulans BC01, isolated from thick broad-bean sauce. B. coagulans BC01 is widely used in China, where it is considered a treatment for diarrhea, constipation, and allergies and an immunity booster. The complete genome sequence of B. coagulans BC01 will help future research to provide more molecular information about its features and safety.

show abstract

A prospective, interventional, randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of Bacillus coagulans LBSC in the treatment of acute diarrhea with abdominal discomfort

Cited by 29 publications

References 43 publications

Therapeutic efficacy of probiotic Alkalihalobacillus clausii 088AE in antibiotic-associated diarrhea: A randomized controlled trial

Therapeutic efficacy of probiotic Alkalihalobacillus clausii 088AE in antibiotic-associated diarrhea: A randomized controlled trial

Isolation of food-derived bacteria inducing interleukin-22 in B cells

Complete Genome Sequence of Bacillus coagulans BC01, a Promising Human Probiotic Strain Isolated from Thick Broad Bean Sauce

Contact Info

Product

Resources

About